Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2019—AutoGen has introduced its fully automated Xtract 16+, for nucleic acid purification from molecular diagnostic, biological, clinical, and forensic sample types. The Xtract 16+ offers nucleic acid isolation from liquid biopsies, plasma, serum, and other body fluids and can process up to 16 samples simultaneously.
November 2019—Binding Site’s Immunologicals Group has expanded its line of antibodies and antigens for human coagulation testing applications. Prothrombin and glycerol-free prothrombin proteins are available as antigens, and antibody products include anti-human factor H, factor I, fibrinogen, fibronectin, plasminogen, prothrombin, thrombin, and von Willebrand factor.
November 2019—Thermo Scientific’s Sensititre Gram Negative MDRGN1F AST Plate is now available on the Sensititre AST System. This format offers eravacycline, omadacycline, and plazomicin on an FDA-cleared, IVD-labeled microbroth dilution susceptibility plate for antimicrobial susceptibility testing using second-line multidrug-resistant organism therapies with expanded dilution ranges for Gram-negative organisms.
November 2019—A study conducted by Medical Database (Leblow L, et al. J Clin Lab Med. Sept. 5, 2019. doi:10.16966/2572-9578.128) showed that its laboratory decision system, LDS, reduced unnecessary test ordering.
November 2019—The U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared involve a new testing paradigm in which two enzyme immunoassays are run concurrently or sequentially, rather than the current two-step process in which a Western blot must be run after the initial EIA test.
November 2019—Memorial Sloan Kettering Cancer Center announced that the New York State Department of Health has issued an approval for its Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS) molecular assay. MSK-ACCESS was developed in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and has been clinically validated and implemented by members of MSK’s molecular diagnostics service.
November 2019—Randox introduced a research use only sPLA2-IIA assay for use on a range of clinical chemistry analyzers. The latex-enhanced immunoturbidimetric assay measures sPLA2-IIA mass levels.
November 2019—ChromaCode announced publication of a study by the Medical College of Wisconsin, Milwaukee, and Gundersen Medical Foundation, La Crosse, Wis., highlighting the performance and utility of the High-Definition PCR Tick-Borne Pathogen Panel RUO.
November 2019—Alcor Scientific introduced the miniiSED, the newest addition to its iSED family of erythrocyte sedimentation rate analyzers.
Biocare Medical released a mouse monoclonal antibody, p16 INK4a, for in vitro diagnostic use in the qualitative identification of the p16 INK4a protein by immunohistochemistry in formalin-fixed, paraffin-embedded human tissues.
